Search

Juliana M Woda

from Shaker Heights, OH
Age ~50

Juliana Woda Phones & Addresses

  • 2686 Wadsworth Rd, Beachwood, OH 44122
  • 1783 Middlehurst Rd, Cleveland, OH 44118 (216) 321-7341
  • 3193 Onaway Rd, Cleveland, OH 44120 (216) 752-0436
  • Shaker Heights, OH
  • 116 Elgin St, Newton Center, MA 02459 (617) 969-8288
  • 2 Peabody Ter, Cambridge, MA 02138 (617) 491-0116
  • Shaker Hts, OH

Work

Position: Professional/Technical

Resumes

Resumes

Juliana Woda Photo 1

Manager, Translational Research At Juventas Therapuetics, Inc

View page
Position:
Manager, Translational Research at Juventas Therapuetics, Inc
Location:
Cleveland/Akron, Ohio Area
Industry:
Biotechnology
Work:
Juventas Therapuetics, Inc - Cleveland, OH since Nov 2012
Manager, Translational Research

Athersys Jan 2011 - Dec 2012
Senior Scientist

Athersys Aug 2008 - Dec 2010
Scientist

Massachusetts General Hospital 2002 - 2008
Research Fellow
Education:
Harvard University 1996 - 2002
PhD, Cell and Developmental Biology
Rutgers, The State University of New Jersey-New Brunswick 1992 - 1996
BA, Molecular Biology and Biochemistry
Juliana Woda Photo 2

Juliana Woda

View page

Publications

Us Patents

Modulation Of Angiogenesis

View page
US Patent:
20110206647, Aug 25, 2011
Filed:
Mar 25, 2011
Appl. No.:
13/071793
Inventors:
Juliana Megan Woda - Shaker Heights OH, US
Anthony E. Ting - Shaker Heights OH, US
Nicholas A. Lehman - Solon OH, US
Assignee:
ABT Holding Company - Cleveland OH
International Classification:
A61K 35/12
C12N 5/071
C12Q 1/02
A61P 9/00
US Classification:
424 937, 435374, 435 29, 435325, 435375
Abstract:
The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.

Use Of Stem Cells To Reduce Leukocyte Extravasation

View page
US Patent:
20140037596, Feb 6, 2014
Filed:
Oct 10, 2013
Appl. No.:
14/051164
Inventors:
Juliana Megan WODA - Shaker Heights OH, US
Wouter VAN'T HOF - Shaker Heights OH, US
Assignee:
ABT Holding Company - Cleveland OH
International Classification:
G01N 33/50
A61K 35/42
A61K 35/44
G01N 33/569
US Classification:
424 937, 435325, 435 792, 435 612, 435 71, 435 724, 435 34, 435366
Abstract:
The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.

Use Of Stem Cells To Reduce Leukocyte Extravasation

View page
US Patent:
20110020293, Jan 27, 2011
Filed:
Jul 21, 2010
Appl. No.:
12/840722
Inventors:
Juliana Megan Woda - Shaker Heights OH, US
Wouter Van't Hof - Shaker Heights OH, US
Assignee:
ABT Holding Company - Cleveland OH
International Classification:
A61K 35/12
A61P 29/00
C12Q 1/04
C40B 50/06
C12N 5/02
US Classification:
424 937, 435 34, 506 26, 435375
Abstract:
The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.

Modulation Of Angiogenesis

View page
US Patent:
20140242629, Aug 28, 2014
Filed:
Feb 25, 2014
Appl. No.:
14/189474
Inventors:
Juliana Megan Woda - Shaker Heights OH, US
Anthony E. Ting - Shaker Heights OH, US
Nicholas A. Lehman - Solon OH, US
Assignee:
ABT Holding Company - Cleveland OH
International Classification:
C12N 5/074
US Classification:
435 29, 435375
Abstract:
The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.
Juliana M Woda from Shaker Heights, OH, age ~50 Get Report